Nadine Attal (University Versailles Saint Quentin, Versailles, France) shared with us her expert opinion on the controversial topic of therapeutic cannabis for neuropathic pain.
1. What advantages does cannabis offer compared to current pharmacological treatments for neuropathic pain? (0:05)
2. What can we conclude about the clinical evidence to date? (0:41)
3. What have we learned about the safety and potential long-term effects of therapeutic cannabis for neuropathic pain? (2:22)
4. Which patients are most likely to benefit from cannabis for pain relief and in which patients is it contraindicated? (3:34)
5. This is a very controversial issue. What other pros and cons should be considered? (4:46)
Speaker disclosure: Nadine Attal has received honoraria from Pfizer, Lilly, Aptynix, Sanofi, MSD, Novartis, Grunenthal, Ipsen over the past 3 years outside participation in this interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
Share this Video
Related Videos In Neuropathic Pain
Erika Petersen, AAN 2021: Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy
We were delighted to speak with Prof. Erika Petersen (University of Arkansas for Medical Sciences, Little Rock, AR, USA) around the six month results from the SENZA-PDN study. The abstract entitled: ‘Sustained Benefits for 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy—Six Month Results from a Multicenter Randomized Controlled Trial’ was presented at […]
José A. López García, EAN 2021: Clinical Development of SAN711, and its Potential to Treat Neuropathic Pain
It was a pleasure to meet with José A. López García (University of Alcalá, Alcalá de Henares, Spain) to discuss the clinical development of SAN711, a selective GABAA α3 receptor positive allosteric modulator for the potential treatment of neuropathic pain. The abstract entitled: ‘SAN711 a selective GABAA α3 receptor positive allosteric modulator as a novel […]
Raili Kauppinen, EAN 2020 – ENVISION Study in Patients With Acute Hepatic Porphyria
Raili Kauppinen (University Hospital of Helsinki, Finland) shares key findings and insights into the ENVISION study, which evaluated the efficacy and safety of givosiran, a subcutaneously administered RNA interference therapeutic targeting aminolevulinic acid synthase 1, in patients with acute hepatic porphyrias (ClinicalTrials.gov Identifier: NCT03338816). Questions 1. Could you give us a brief overview of acute […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!